Roche has solidified its strategic pivot toward the Chinese biotechnology sector by entering into a landmark $400 million partnership with…
Read More
Roche Secures FDA Approval for Tecentriq in Stage III dMMR Colon Cancer Setting to Establish New Treatment Paradigm
The pharmaceutical landscape for gastrointestinal oncology has undergone a significant transformation following a landmark regulatory decision by the US Food…
Read More
Roche Acquires Global Rights to Alector’s Parkinson’s Disease Candidate AL050 in Landmark $1.27bn Deal
Swiss pharmaceutical giant Roche has secured global rights to Alector’s prominent preclinical Parkinson’s disease candidate, AL050, in a lucrative transaction…
Read More
Roche Deepens AI and Small Molecule Strategy with Multi-Billion-Dollar Partnerships in Oncology and CVRM
Swiss pharmaceutical giant Roche, acting through its subsidiary Genentech, has entered a blockbuster agreement with Earendil Labs, committing up to…
Read More
Roche and Dualitas Therapeutics Ink Billion-Dollar Partnership to Advance Next-Generation Bispecific Antibodies in Immunology and Inflammation
In a landmark agreement that underscores the surging therapeutic potential of proximity biology, Swiss pharmaceutical giant Roche has joined forces…
Read More
AMSBIO Biospecimens Fuel Landmark Roche Study Uncovering Fibroblast Activation Protein’s Critical Role in Cancer Immunotherapy
A collaborative research effort, leveraging extensively characterized biospecimens provided by AMSBIO, has yielded groundbreaking insights into the multifaceted role of…
Read More
BMS claims pharma’s most powerful AI supercomputer. How it stacks up to Lilly’s and Roche’s.
Bristol Myers Squibb (BMS) announced Monday its plans to deploy an NVIDIA DGX SuperPOD, a cutting-edge, prepackaged supercomputing platform designed…
Read More
FDA Grants Priority Review to Roche’s Giredestrant for Early-Stage Breast Cancer, Signaling Potential Paradigm Shift in Adjuvant Therapy
The US Food and Drug Administration (FDA) has accepted priority review of the new drug application (NDA) for Roche’s investigational…
Read More
Roche and C4 Therapeutics Forge Strategic Alliance to Pioneer Degrader-Antibody Conjugates for Novel Cancer Therapies
Roche and C4 Therapeutics Forge Strategic Alliance to Pioneer Degrader-Antibody Conjugates for Novel Cancer Therapies Roche, a global pharmaceutical giant,…
Read More
